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University of Minnesota, Minneapolis, MinnesotaABSTRACT Calmodulin (CaM) binding to the type 2 ryanodine receptor (RyR2) regulates Ca release from the cardiac sarco-
plasmic reticulum (SR). However, the structural basis of CaM regulation of the RyR2 is poorly defined, and the presence of other
potential CaM binding partners in cardiac myocytes complicates resolution of CaM’s regulatory interactions with RyR2. Here, we
show that a fluorescence-resonance-energy-transfer (FRET)-based approach can effectively resolve RyR2 CaM binding, both
in isolated SR membrane vesicles and in permeabilized ventricular myocytes. A small FRET donor was targeted to the RyR2
cytoplasmic assembly via fluorescent labeling of the FKBP12.6 subunit. Acceptor fluorophore was attached at discrete positions
within either the N- or the C-lobe of CaM. FRET between FKBP12.6 and CaM bound to SR vesicles indicated CaM binding at
a single high-affinity site within 60 A˚ of FKBP12.6. Micromolar Ca increased the apparent affinity of CaM binding and slowed
CaM dissociation, but did not significantly affect maximal FRET efficiency at saturating CaM. FRET was strongest when the
acceptor was attached at either of two positions within CaM’s N-lobe versus sites in CaM’s C-lobe, providing CaM orientation
information. In permeabilized ventricular myocytes, FKBP12.6 and CaM colocalized to Z-lines, and the efficiency of energy trans-
fer to both the N- and C-lobes of CaMwas comparable to that observed in SR vesicle experiments. Results also indicate that both
the location and orientation of CaM binding on the RyR2 are very similar to the skeletal muscle RyR1 isoform. Specific binding of
CaM to functional RyR2 channels in the cardiac myocyte environment can be monitored using FKBP biosensors and FRET.INTRODUCTIONCalmodulin (CaM) is a versatile intracellular Ca sensor,
capable of modulating the activity of diverse binding part-
ners. CaM is comprised of roughly symmetrical N- and
C-lobes that are joined by a flexible hinge (1,2). Ca binding
at EF hand motifs within CaM’s N- and C-lobes evokes
conformational changes within CaM that expose hydro-
phobic residues and transduce intracellular Ca signals (3).
Among CaM’s many binding partners are various ion chan-
nels (4), including the large intracellular Ca release channels
known as ryanodine receptors (RyRs), which are central to
excitation-contraction coupling in cardiac and skeletal
muscle (5–7).
CaM binding to the cardiac RyR2 channel isoform causes
a rightward shift in the steady-state [Ca]-dependence of
RyR2 activation in sarcoplasmic reticulum (SR) vesicles
(8), a decrease in the frequency and duration of channel
opening events in lipid bilayers (9), and a decrease in the
frequency of Ca sparks in permeabilized myocytes (10).
Meissner and co-workers have demonstrated that the specific
disruption of RyR2 CaM binding by targeted substitutions
within a core CaM binding sequence results in severe cardiac
hypertrophy and early death in mutant mice (11). CaM regu-
lation of RyR2 is therefore crucial for normal cardiac func-
tion and development. However, efforts to resolve CaM’s
functional interactions with the RyR2 specifically haveSubmitted July 5, 2011, and accepted for publication September 22, 2011.
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partners that are also present in the cardiac myocyte,
including calcineurin, CaM-dependent protein kinase II,
and L-type Ca channels (12–14). In addition, the structural
basis of RyR2 regulation by CaM remains poorly defined,
as 3Dmapping of CaM binding by cryo-electron microscopy
(cryo-EM) and fluorescence resonance energy transfer
(FRET) has thus far been limited to the skeletal muscle
RyR1 isoform (7). RyR1 and RyR2 exhibit important iso-
form differences in CaM regulation, including differences
in the functional effect of CaM binding at submicromolar
Ca (8), the molecular determinants of binding (15), and the
thermodynamics of binding (16). Whether these isoform
differences reflect major differences in the location or orien-
tation of CaM binding to the different channel isoforms is not
yet clear, and this study aims to help clarify these issues.
In the case of the RyR1 isoform, 3D cryo-EM indicates
that CaM binds adjacently to the cleft that separates the
handle and clamp regions of the cytoplasmic assembly
(17,18). This places CaM near the base of a major structural
hinge involved in the translation of large-scale motions of
the cytoplasmic and transmembrane assemblies (19). The
location of CaM binding predicted by cryo-EM was sup-
ported by FRET mapping of CaM bound to the RyR1 iso-
form (20). These FRET studies further demonstrated that
CaM binds to RyR1 in an extended conformation, oriented
with its N-lobe nearer to, and its C-lobe farther from,
a donor-labeled FKBP subunit. Given the functional differ-
ence in effects of CaM on RyR2 versus RyR1 gating (8), it isdoi: 10.1016/j.bpj.2011.09.030
FKBP-Calmodulin FRET on Cardiac RyR2 2171possible that the relative positions of FKBP and CaM could
differ among RyR isoforms.
Here, we use FRET to characterize CaM binding to the
RyR2 channel isoform. We examine whether our approach
based on site-directed fluorescent labeling of CaM and
FKBP12.6 can effectively resolve CaM’s interactions with
the RyR2, both in SR vesicle preparations and in the more
physiological environment of permeabilized ventricular
myocytes. We also examine whether CaM’s location and
orientation when bound to the RyR2 are similar to what
has been demonstrated previously for the RyR1 macro-
molecular complex.METHODS
Synthesis of fluorescent CaMs and FKBP12.6
Fluorescent probes Alexa Fluor 488 C5 maleimide and Alexa Fluor 568 C5
maleimide were purchased from Invitrogen/Molecular Probes (Carlsbad,
CA). Fluorescent derivatives of single-cysteine mutants of CaM and
FKBP12.6 were prepared and labeled as previously described (20–22).
CaM mutants T26C, T34C, Y99C, and T110C were labeled with red-fluo-
rescent Alexa 568 and used as acceptors in FRET experiments. FKBP12.6
was labeled at position 14 or 49 with green-fluorescent Alexa 488 and used
as donor in FRETexperiments. Stoichiometric labeling of fluorescent CaMs
(F-CaMs) and FKBP (F-FKBP) was demonstrated by the absorbance of the
bound dye and SDS-PAGE densitometry and confirmed by MALDI-TOF
mass spectrometry to R95%. The capability of F-CaMs to bind and
regulate RyRs was tested in measurements of [3H]ryanodine binding to
SR vesicles, as described previously (20).FRET between F-CaMs and F-FKBP bound
to SR vesicles
Cardiac SR vesicles were isolated from fresh homogenates of pig ventric-
ular muscle by differential centrifugation in ice-cold buffers containing
protease inhibitors (23) and stored at 80C. Skeletal muscle heavy SR
vesicles were isolated from pig longissimus dorsi (23). FRET samples
were prepared as described (20,21). Briefly, SR vesicles (0.4 mg/ml)
were incubated with 50 nM F-FKBP for 90 min at 37C, then spun down
(100,000  g) to remove unbound F-FKBP. The membrane pellet was
homogenized and resuspended to a final protein concentration of 10 mg/ml,
then used immediately to prepare FRET samples. Fluorescence emission
spectra were acquired using a Molecular Devices Gemini EM microplate
reader with a 1 J/flash xenon lamp as the excitation source. FRET was
measured after incubation of donor-labeled SR vesicles (3 mg/ml final)
with acceptor-labeled CaMs in media containing 150 mM KCl, 20 mM
K-PIPES (pH 7.0), 5 mM GSH, 1 mM EGTA (pH 7.0), 0.1 mg/ml BSA,
1 mg/ml aprotinin/leupeptin, and sufficient CaCl2 to achieve the desired
free [Ca] (as calculated using MaxChelator software, http://maxchelator.
stanford.edu). The intrinsic fluorescence of F-FKBP and F-CaMs in solu-
tion was unaffected by [Ca]. FRET efficiencies (E) were calculated from
the decrease in donor steady-state fluorescence (FD) due to the presence
of acceptor (FDA):
E ¼ 1

FDA
FD

: (1)
Donor-acceptor distances, R, were calculated from
R ¼ R0

FRET1  11=6; (2)where the Fo¨rster distance, R0, is defined as the distance at which FRET ¼
0.5 (62 A˚ for the Alexa 488-Alexa 568 donor-acceptor pair (24)). F-CaM
association data were fit to a double-exponential association model (25)
that includes a fast and a slow phase, the latter likely dependent on the
dissociation of a fraction of endogenous CaM that remains bound to iso-
lated SR vesicles (25,26). F-CaM dissociation data were fit to a single expo-
nential decay (25,26). Maximal FRET efficiencies (Emax) and F-CaM
affinity constants (Kd) were calculated from F-CaM binding isotherms
according to
E ¼ Emax½F-CaMðKd þ ½F-CaMÞ: (3)FRET between F-CaMs and F-FKBP in
permeabilized rat ventricular myocytes
Isolation of rat ventricular myocytes was carried out essentially as
described (10). All procedures were approved by the Institutional Animal
Care and Use Committees. Ventricular myocytes were superfused with re-
laxing solution containing 0.1 mM EGTA, 5 mM ATP, 10 mM HEPES,
150 mM potassium aspartate, 0.25 mM MgCl2, and 10 mM GSH, at
23C. The sarcolemma was permeabilized with 50 mg/ml saponin for
30 s. After permeabilization, myocytes were placed in internal solution
composed of 1 mM EGTA, 10 mM HEPES, 120 mM K-aspartate, 5 mM
ATP, 1 mM MgCl2, 10 mM GSH, 30 nM free [Ca] (calculated using Max-
Chelator), 10 mM phosphocreatine, 5 I.U./ml creatine phosphokinase, 4%
dextran (Mr, 40,000), pH 7.2. Fluorescent FKBP12.6 and CaM were added
to the bath as previously described (22,25) at the concentrations indicated.
All experiments were performed at 23C.
Confocal images were acquired using a Biorad (Hercules, CA) Radiance
2100 laser-scanning confocal microscope equipped with an argon ion laser,
green helium-neon laser, and a Nikon Fluo 40 oil lens (NA 1.3). F-FKBP
fluorescencewas excited at 488 nm, and emission was recorded using a 515/
15 nm bandpass filter. F-CaM fluorescence emission was recorded using
a 600-nm long-pass filter for both direct excitation at 543 nm and FRET
associated with 488 nm excitation. Cross talk, either donor fluorescence
in the red (>600 nm) channel or acceptor fluorescence at >600 nm excited
directly by 488-nm illumination, was <5% and only present in the red
channel. FRET efficiency was calculated from donor quench upon F-CaM
addition (using Eq. 1) and by enhanced donor fluorescence upon acceptor
photobleach: E ¼ 1 – (FD-prebleach/FD-postbleach).RESULTS
FRET detection of CaM binding to cardiac
SR vesicles
We previously showed that F-CaM binding is highly
concentrated at Z-lines in permeabilized ventricular myo-
cytes and in patch-clamped intact cells (25). To better
resolve CaM interactions specifically with RyR2, we first
examined changes in the fluorescence of F-FKBP (labeled
at position 49) bound to RyR2 in isolated cardiac SR vesi-
cles. Upon excitation at 488 nm, samples containing the
F-FKBP donor alone displayed a single fluorescent peak
at 520 nm (Fig. 1 A, solid curve). Repeated excitation of
donor-only samples (every 10 s for 10 min) demonstrated
no significant loss of donor fluorescence due to photo-
bleaching (F520 nm decreased 0.8 5 0.1% after 10 min).
Addition of an acceptor-labeled F-CaM (600-nm peak;
Fig. 1 A, dotted curve) resulted in a rapid and pronouncedBiophysical Journal 101(9) 2170–2177
FIGURE 1 FRET detection of F-CaM association and dissociation. (A)
Spectra of F-FKBP (donor) bound to pig cardiac SR vesicles before (solid
line) and 1 h after (dotted line) addition of 400 nM F-CaM (acceptor) with
300 mM Ca. (B) Time course of F-CaM association in media containing
either 100 nM or 300 mM Ca. (C) Recovery of F-FKBP fluorescence
upon F-CaM dissociation with 300 mM Ca. After allowing F-CaM binding
to reach equilibrium (solid line), samples were diluted into media contain-
ing a 50-fold excess of nonfluorescent CaM for 1 h (dotted line). (D) Time
course of F-CaM dissociation in media containing 100 nM or 300 mM Ca.
Data are from single experiments, representative of at least three similar
experiments. Curves in B and D are fits to a double-exponential association
and single-exponential dissociation equations, respectively (Methods; fit
parameters are in Table 1). F-CaM was labeled at position 34 (N-lobe).
2172 Guo et al.quench of F-FKBP fluorescence (i.e., FRET), consistent
with F-CaM binding in close proximity to F-FKBP. Time
courses of FRET in media containing either 100 nM or
300 mM Ca are shown in Fig. 1 B. These data demonstrate
rapid binding of F-CaM at both [Ca]s, consistent with
binding of both the apo- and Ca-CaM species. Binding ap-
proached an apparent equilibrium more rapidly in 100 nM
Ca, although FRET was greater at 300 mM Ca at all time
points. We next examined F-CaM dissociation after addition
of a 50-fold excess of nonfluorescent CaM. Spectra in
Fig. 1 C show that 1 h after the addition of nonfluorescent
CaM, F-FKBP fluorescence (520 nm) was restored to the
level observed in the absence of F-CaM (Fig. 1 A), indi-TABLE 1 Fitting parameters for F-CaM association and dissociatio
F-CaM association
Ys ts (min) Yf
100 nM Ca 0.135 0.01 5.55 0.5 0.165 0.
300 mM Ca 0.225 0.03 8.55 0.6 0.155 0.
Parameter fits are to the association and dissociation curves shown in Fig. 1, B
Biophysical Journal 101(9) 2170–2177cating displacement of F-CaM from binding sites near
F-FKBP. Time courses of F-CaM dissociation (Fig. 1 D)
further showed that the rate of F-CaM dissociation was
slowed by a factor of 4 when Ca was increased from
100 nM to 300 mM (t ¼ 37 s for the former vs. 2.5 min
for the latter; Table 1). These results are consistent with
time constants of [35S]CaM dissociation from RyR reported
previously (26), and with the effect of Ca in slowing the rate
of F-CaM dissociation from Z-lines in permeabilized myo-
cytes (25).
To characterize the steady-state binding of F-CaM using
our FRET assay, we measured energy transfer between
F-FKBP and F-CaM after 2 h incubation. Spectra in Fig. 2 A
show that addition of increasing concentrations of F-CaM
(10–500 nM) evoked a progressive decrease in F-FKBP
fluorescence at 520 nm. Plots of FRET as a function of
F-CaM in 100 nM and 300 mM Ca are shown in Fig. 2 B.
At both [Ca]s, FRET data were well fit by models assuming
F-CaM binding at a single saturable site. Micromolar [Ca]
increased the apparent affinity of CaM binding approxi-
mately fourfold (Kd ¼ 93 5 1 nM versus 26 5 1 nM, in
100 nM and 300 mM Ca, respectively). However, the
maximal FRET efficiency was similar at these different
[Ca]s (Emax ¼ 0.58 5 0.02 vs. 0.57 5 0.01, in 100 nM
and 300 mM Ca, respectively). These Emax values corre-
spond to distances of 59 5 2 A˚ in 100 nM Ca and 59 5
1 A˚ in 300 mM Ca, and they are in good agreement
with our previous determinations (Table 1 in our previous
work (21)). We conclude that Ca did not substantially alter
the proximity of the FRET probes attached at FKBP12.6
(position 49) and CaM’s N-lobe (position 34). Rather,
the increased FRET observed at 300 mM Ca and subsaturat-
ing F-CaM more likely reflects the increased binding
affinity and increased occupancy of RyR2 CaM sites at
the higher [Ca].
The approximately fourfold increase in F-CaM binding
affinity in micromolar Ca (Fig. 2 B) could be explained by
Ca binding to CaM itself, or by Ca binding to and activation
of RyR2. To distinguish between these possibilities, we used
a Ca-insensitive CaMmutant (CaM1234), in which an E-to-A
substitution has been introduced into each of CaM’s four EF
hands (20,23). Fig. 2 C shows that the marked effect of Ca
on F-CaM binding affinity was largely lost when using the
F-CaM1234 mutant (Kd ¼ 90 5 3 nM vs. 74 5 3 nM, in
100 nM and 300 mM Ca, respectively). Thus, regardless of
[Ca], F-CaM1234 bound with an affinity comparable to that
of F-CaM in 100 nM Ca (Fig. 2 B). Maximal FRETn
F-CaM dissociation
tf (s) Y t
01 395 2.0 0.295 0.01 375 2.1 s
01 14 5 6 0.335 0.01 2.55 0.1 min
and D.
FIGURE 2 FRET detection of equilibrium binding of F-CaMs to cardiac
SR vesicles. (A) Spectra with 100 nM Ca (Ex 488 nm), where unlabeled
curves are þ10, 30, 60, 100, 300, and 400 nM F-CaM. (B) F-CaM depen-
dence of FRET in 100 nM and 300 mM Ca. Data represent the mean5 SE
from four paired experiments. Solid lines are fits to a single rectangular
hyperbola (Kd ¼ 93 5 1 nM and Emax ¼ 0.58 5 0.02 in 100 nM Ca;
Kd ¼ 26 5 1 nM and Emax ¼ 0.57 5 0.01 in 300 mM Ca). (C) Binding
of a Ca-insensitive CaM mutant (F-CaM1234) detected by FRET (n ¼ 3
experiments).
FIGURE 3 Inhibition of FRET by suramin and rapamycin. (A) Samples
were incubated for 2 h in 25Cmedia with 100 nM F-CaM and the indicated
[suramin]. Data represent the mean5 SE from three experiments. Lines are
fits to the Hill equation (Ki ¼ 4.15 0.2 mM and nH ¼ 2.4 in 100 nM Ca;
Ki ¼ 10 5 0.7 mM and nH ¼ 2.4 in 300 mM Ca). (B) Incubations in
rapamycin were for 3 h at 37C, to increase F-FKBP dissociation from
RyR2. Data represent the mean5 SE from two experiments (Ki ¼ 1735
28 nM and nH ¼ 1.0 in 100 nM Ca; Ki ¼ 1905 18 nM and nH ¼ 1.1 in
300 mM Ca).
FKBP-Calmodulin FRET on Cardiac RyR2 2173efficiencies for F-CaM1234 were also similar at 100 nM and
300 mM Ca (Emax ¼ 0.62 5 0.01 vs. 0.585 0.01, respec-
tively). We conclude that the Ca-dependent increase in
F-CaM affinity to RyR2 is primarily due to Ca binding to
CaM, and not Ca binding to RyR2 per se.Inhibition of FRET by suramin and rapamycin
Suramin directly binds to the core RyR CaM binding
sequence and displaces CaM from both RyR1 and RyR2
channel isoforms (27–29). We used suramin to block CaM
binding to RyR2 and thereby test the hypothesis that our
FRET signal is strictly a function of CaM binding to the
RyR2 (versus other potential CaM sites on the SR). Suramin
inhibited FRET in a concentration-dependent manner
(Fig. 3 A). In media containing 100 nM Ca, FRETwas abol-
ished by R20 mM suramin (Ki ¼ 4.1 mM). Suramin also
inhibited FRET in 300 mM Ca (Ki ¼ 10 mM), and high sur-
amin (30–100 mM) reduced FRET to 5% of the values
without drug. Under these conditions, suramin does not
significantly dissociate, or alter the fluorescence signal of,
F-FKBP.
To verify that FRET was also dependent on F-FKBP
binding to RyR2 channels, we tested the effect of rapamycinon FRET. Rapamycin prevents FKBP12.6 binding to RyR2
by complexing with free FKBP12.6 and preventing its
rebinding to RyR2 channels (22). Fig. 3 B shows the [rapa-
mycin] dependence of FRET inhibition after 3 h incubation
with drug. Rapamycin inhibition of FRET was similar at
100 nM and 300 mM Ca (Ki ¼ 173 and 190 nM, respec-
tively), and high rapamycin (10 mM) reduced FRET to 6%
of control values. Results shown in Fig. 3, A and B, therefore
indicate that displacement of either CaM or FKBP12.6 from
RyR2 channels eliminates ~95% of the FRET signal
observed in cardiac SR vesicles. We infer that non-RyR2
sites are unlikely to contribute to our FRET measurements.Orientation of CaM on RyR2
To test whether CaM’s location and orientation when bound
to the RyR2 are similar to its location and orientation on the
RyR1 isoform (20), we directly compared FRETefficiencies
obtained using cardiac and skeletal muscle SR vesicles. For
these experiments, the acceptor was attached at one of four
different positions within CaM. Labeling sites within CaM’s
N-lobe were at position 26 (within EF hand 1) and position
34 (as in Figs. 1–3). The corresponding labeling sites within
CaM’s C-lobe were at position 99 (within EF hand 3) and
position 110. All F-CaMs were tested at 500 nM, to
approach saturation of RyR CaM sites and maximize
FRET signals. Fig. 4 shows that energy transfer to each of
the two N-lobe positions was strong (E > 0.36), regardless
of whether CaM was bound to SR vesicles prepared from
skeletal muscle (Fig. 4 A) or cardiac muscle (Fig. 4 B). In
contrast, FRET to each of the two positions in CaM’s
C-lobe was substantially weaker (E < 0.18), indicating
that this lobe is located farther from FKBP12.6 when bound
to SR vesicles from either muscle type. This clear differenceBiophysical Journal 101(9) 2170–2177
FIGURE 4 FRET indicates similar orientation of CaM when bound to
RyR1 versus RyR2. SR vesicles isolated from skeletal muscle (A) or cardiac
muscle (B) were preincubated with F-FKBP donor, then incubated with
F-CaMs (500 nM) labeled with acceptor at one of four different positions
(26, 34, 99, or 110, as indicated). Data represent the mean5 SE from three
(A) or four (B) experiments. FRET efficiencies in B did not differ signifi-
cantly from the corresponding values in A, except where indicated by the
asterisk (p ¼ 0.04, Student’s t-test).
2174 Guo et al.in FRET to CaM’s N- versus C-lobes held true at both
100 nM and 300 mM [Ca]. Remarkably, position-by-position
statistical comparisons of FRET efficiencies in cardiac
versus skeletal SR at each [Ca] indicated only one minor
difference out of eight comparisons (position 34 on CaM
at 300 mM Ca; E ¼ 0.53 5 0.01 for RyR1 vs. 0.61 5
0.03 for RyR2, p ¼ 0.04). Results shown in Fig. 4 therefore
indicate that distance relationships between the FKBP and
CaM subunits are very similar for the RyR1 and RyR2
isoforms. In addition, the remarkable similarity of FRET
efficiencies measured using the different membrane prepa-
rations, and at both high and low Ca, further supports the
likelihood that FRET reports on CaM binding to RyRs
specifically.FRET between CaM and FKBP12.6 in cardiac
myocytes
We have previously shown that both F-CaM binding (13,25)
and F-FKBP binding (22) are concentrated at Z-lines in
the more physiological setting of permeabilized ventricularBiophysical Journal 101(9) 2170–2177myocytes. To investigate FRET between F-CaMs and
F-FKBPs in the myocyte environment, we measured FRET
efficiencies using two protocols: first, by monitoring donor
quenching by the acceptor, and second, by monitoring the
increase in donor fluorescence after acceptor photobleach-
ing. Fig. 5 A (upper) shows the distinctive striated RyR2
localization pattern with 100 nM F-FKBP in the myocyte
(green; Em ¼ 500–530 nm) and very low signal in the
long-wavelength acceptor channel (red; Em > 600 nm).
When N-lobe labeled F-CaM (1 mM) is added (Fig. 5 A,
lower), there is both quench of F-FKBP fluorescence (green)
and readily detectable F-CaM fluorescence (red) with the
same spatial pattern. This F-CaM concentration is sufficient
to nearly saturate the myocyte CaM binding sites at 50 nM
free [Ca] where the K1/2 ¼ 31 nM (13). In a similar way, the
K1/2 for FKBP12.6 in this type of experiment is ~1 nM (22),
so RyR2 is also essentially saturated with F-FKBP. The
FRET efficiency calculated from the fractional decrease in
F-FKBP fluorescence was 0.445 0.02 (n ¼ 3 cells).
After both F-FKBP and F-CaM are preequilibrated in a
permeabilized myocyte (Fig. 5 B), we can bleach the F-CaM
acceptor and measure the increase in donor F-FKBP
fluorescence. In the case shown, we selectively bleached
F-CaM (at 543 nm) only in the central region of the myocyte,
and donor fluorescence is enhanced only in that region. In
control experiments in which the photobleaching protocol
was repeated in myocytes perfused with F-FKBP donor
only, no such increase in donor fluorescence was observed
(not shown). The average efficiency of FRET between
F-FKBP and F-CaM assessed by acceptor photobleaching
was 0.36 5 0.03 (n ¼ 12), in good agreement with results
obtained by the donor quenching procedure. Thus, results
in Fig. 5, A and B, demonstrate robust FRET between
FKBP12.6 and the N-lobe of CaM in permeabilized
myocytes. Moreover, this FRET efficiency (36–44%) in the
cellular setting matches well with that seen in SR vesicles
between the N-lobe of CaM and FKBP at 100 nM [Ca].
This suggests that the relative localization of these proteins
on the RyR in the myocyte is quite similar to that seen in
the more isolated SR system.FIGURE 5 FRET between F-FKBP (donor) and
F-CaM (acceptor) in permeabilized rat cardiomyo-
cytes. (A) F-FKBP quench after addition of F-CaM.
Myocytes were incubated with F-FKBP (100 nM)
for 10 min to reach steady-state binding to RyRs,
then incubated with F-FKBP (100 nM) and
F-CaM (1 mM) for 20 min. (B) Permeabilized
myocytes were incubated with F-FKBP (100 nM)
and F-CaM (1 mM) for 30 min to assure steady-
state FRET. Then regions of interest (ROI) were
chosen and illuminated by 543 nm green HeNe
laser (to photobleach the acceptor) at high laser
power (80%) for 45 s. F-FKBP fluorescence
increases after F-CaM photobleach. Both experi-
ments used F-CaM labeled within the N-lobe (posi-
tion 26).
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FRET is sensitive to suramin (which binds to the RyR2
CaM binding domain). Before the addition of suramin,
localized binding of both F-FKBP (green striations),
F-CaM (red striations with direct Ex 543), and FRET (red
striations with Ex 488) are evident. The addition of suramin
(25 mM) nearly abolished the red striations at both excitation
wavelengths, consistent with the displacement of CaM from
RyR2 channels and prevention of FRET. This effect of sur-
amin on F-CaM binding is most clear in the righthand panels
in Fig. 6, which show fluorescence at >600 nm in response
to direct excitation of F-CaM at 543 nm. Most of the F-CaM
binding at the Z-line (53.7 5 2.6%, n ¼ 5) was also abol-
ished, consistent with the idea that a major fraction of
F-CaM binding at that location is RyR-bound. It is impor-
tant to note that F-FKBP binding was not abolished by
suramin. Rather, F-FKBP fluorescence increased after
F-CaM displacement by suramin (by 425 0.03% increase
in Z-line fluorescence at 500–530 nm). The effect of sura-
min on F-FKBP fluorescence (Fig. 6) is thus comparable
to the effect of acceptor photobleaching (Fig. 5 B), and indi-
cates that FRET in the myocyte environment is strictly
dependent on the F-CaM binding to RyR2 channels.
A hallmark of the F-CaM binding to RyR channels in SR
vesicle experiments (Fig. 4) is that FRET is substantially
weaker when an acceptor is attached within the C-lobe
versus the N-lobe of CaM. Fig. 7 A shows an experiment ex-
amining FRET between F-FKBP and CaM’s C-lobe in per-
meabilized myocytes. Note that photobleaching of F-CaM
resulted in only a small increase in F-FKBP fluorescence
(FRET ¼ 0.029 5 0.005; n ¼ 12). Modest FRET to the
CaM C-lobe was confirmed in FRET measurements assess-
ing the quench of F-FKBP fluorescence upon addition of the
F-CaM acceptor (FRET ¼ 0.13 5 0.01; n ¼ 4). Fig. 7 B
summarizes FRET efficiencies to the N- and C-lobes ofCaM as determined both by acceptor photobleaching and
by donor quenching. Results show that FRET to the
C-lobe of CaM was %25% of that to the N-lobe. Both the
magnitude of these FRET efficiencies in myocytes and
the relative efficiencies of energy transfer to the different
lobes of CaM, were remarkably similar to results obtained
using cardiac and skeletal muscle SR vesicle (Fig. 4 B).
Taken together, these results indicate that our FRET
measurements in isolated SR vesicles reflect the more phys-
iological setting of the permeabilized myocyte, and that
the myocyte FRET is due to specific binding of F-CaMs
to RyR2 channels.DISCUSSION
We show for the first time, to our knowledge, that the
specific binding of CaM to cardiac RyR2 channels can be
monitored using an F-FKBP biosensor and FRET. We
show that this approach reports on RyR2 CaM binding not
only in isolated SR vesicles but also in saponin-permeabi-
lized ventricular myocytes. Because our donor-acceptor
pair can only detect distances of <100 A˚, our FRET
approach effectively resolves CaM’s interactions with
RyR2 channels from its interactions with numerous other
CaM binding partners that are also present in cardiac myo-
cytes and SR vesicles.
The likelihood that our FRET signal reflects donor and
acceptor binding at RyR2 channels is supported by multiple
findings. We find that FRET in cardiac SR vesicles (Fig. 3 A)
and in permeabilized myocytes (Fig. 6) is essentially abol-
ished by suramin, which acts as a competitive inhibitor of
RyR CaM binding, and discriminates among different
CaM targets (27,28). We also find that our FRET signals
are remarkably similar in magnitude across different prepa-
rations, in which the complement of non-RyR bindingFIGURE 6 F-CaM displacement from Z-lines
by suramin. Permeabilized myocytes were incu-
bated with internal solution containing F-FKBP
(100 nM) and F-CaM (1 mM) for 30 min to reach
steady-state FRET. Suramin (25 mM) was added to
dissociate F-CaM from RyRs into the surrounding
bath volume (effectively an infinite sink), such
that bath [F-CaM] is unaltered.
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FIGURE 7 FRET in cardiomyocytes is de-
creased when acceptor is switched from the N- to
the C-lobe of CaM. (A) Recovery of F-FKBP fluo-
rescence after photobleach of F-CaM labeled in the
C-lobe (position 110). (B) Average FRET efficien-
cies to N- and C-lobes of CaM measured by donor
quench and acceptor photobleaching (mean5 SE,
n as indicated).
2176 Guo et al.partners is likely to differ greatly. Thus, we show that FRET
between FKBP12.6 and CaM is similar in experiments using
sucrose-gradient-fractionated skeletal muscle SR vesicles
(Fig. 4 A), cardiac SR vesicles (Fig. 4 B), and saponin-per-
meabilized ventricular myocytes (Fig. 7 B). Steady-state
binding isotherms (Fig. 2) and CaM dissociation kinetics
(Fig. 1 D) derived from FRET measurements are well fit
using models that assume a single population of CaM
binding sites. Furthermore, distances calculated from Emax
determinations are consistent with the proximity of the
FKBP12 and CaM subunits on the same face of the channel
tetramer in RyR1 cryo-EM structural models (18), whereas
FKBP12 and CaM on different faces of RyR1, or on
different channels within an array, are too widely separated
for FRET (20,21). Corresponding high-resolution structures
showing the positions of FKBP12.6 and CaM on the RyR2
isoform are not yet available. However, 3D structures of
RyR1 and RyR2 are very similar overall (7), as are our
measurements of FRET efficiency using the different iso-
forms (Fig. 4). Thus, although we cannot entirely rule out
the possibility that the binding of F-CaMs and/or F-FKBPs
at other targets may contribute to a very small fraction of our
FRET signal, we attribute the vast majority (>95%) of this
signal to FRET between donors and acceptors bound in
close proximity on the same face of RyR2 channels.
These findings also demonstrate that CaM binds RyR2 in
approximately the same position and in the same orientation
as shown previously for RyR1. FRET was markedly
stronger when the acceptor was attached at either of two
positions within CaM’s N-lobe versus positions in CaM’s
C-lobe, indicating that for both RyR isoforms CaM binds
in an extended conformation, with its lobes widely sepa-
rated. We conclude that the important differences in CaM
function on RyR2 versus RyR1 are not linked to gross struc-
tural differences in the location of CaM binding on the 3D
structure of RyR, particularly with respect to the FKBP
location. Micromolar Ca increased the apparent affinity of
RyR2 CaM binding, but did not significantly affect theBiophysical Journal 101(9) 2170–2177maximal FRET efficiency at saturating CaM (Fig. 2).
Thus, we find no evidence for the large-scale Ca-dependent
translocation of CaM that has been demonstrated in RyR1
cryo-EM studies (18).
An intriguing observation arising from this study is that
the apparent Kd for F-CaM binding to the RyR2 in SR
vesicle experiments at physiological diastolic [Ca] of
100 nM (93 nM) is threefold higher than the value of
31 nM that we have measured in permeabilized myocytes
at 50 nM [Ca] using methods similar to those used here
(25). It is not clear what this moderate threefold difference
is attributable to, but factors could include species differ-
ences, small differences in the solutions, differential loss
of partners present in the intact cellular environment, or
subtle differences in structure or modulation (e.g., oxida-
tion, nitrosylation, or phosphorylation). In preliminary
experiments, we were unable to identify a clear explanation.
CaM’s regulatory interactions with RyR2 channels are
critical for normal cardiac function and development, and
altered CaM binding may contribute to defects in SR Ca
handling in arrhythmias and heart failure. CaM is thought
to function as a resident regulatory subunit (5), and results
in this study (Fig. 1) confirm that CaM binding and
unbinding are too slow for us to expect beat-to-beat changes
in the occupancy of RyR2 CaM sites. Indeed, at diastolic
[Ca] of ~100 nM and free [CaM] of 60–100 nM, the
RyR2 would be at least 50–70% saturated with CaM, and
that would be a lower limit compared to the steady state
during normal cardiac function and Ca transients.
If physiological RyR2 saturation with CaM is incomplete,
the inhibitory effect of CaM on RyR2 gating would mean
that either gain or loss of CaM on the RyR could have regu-
latory effects on RyR2 gating. For example, in a rabbit
heart-failure model, Ai et al. (30) found less CaM coimmu-
noprecipitation with RyR2, despite unaltered expression
levels. This reduced CaM bound to RyR2 could thus
contribute to enhanced SR Ca leak in heart failure that
can also be arrhythmogenic, similar to the pathophysiologic
FKBP-Calmodulin FRET on Cardiac RyR2 2177effects seen when knocking in an RyR2 that is defective
in CaM binding (11). Moreover, this CaM-depleted RyR2
phenotype resembles that seen with numerous human
RyR2 mutations associated with catecholaminergic poly-
morphic ventricular tachycardia (31). Our ability to monitor
CaM binding specifically to RyR2 in myocytes using this
FRET approach could be utilized to monitor conditions
that cause CaM (or FKBP) dissociation from the RyR2 in
more physiological and pathophysiological conditions (e.g.,
RyR2 oxidation/nitrosylation, phosphorylation, S100A1
binding).
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